Aegerion Pharmaceuticals (NASDAQ:AEGR) CEO Marc D. Beer acquired 10,000 shares of the stock in a transaction that occurred on Tuesday, May 27th. The stock was purchased at an average price of $31.59 per share, with a total value of $315,900.00. Following the completion of the acquisition, the chief executive officer now directly owns 59,400 shares in the company, valued at approximately $1,876,446. Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) net profit margin is -82.20% and weekly performance is 1.73%. On last trading day company shares ended up $32.35. Analysts mean target price for the company is $75.80. Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) distance from 50-day simple moving average (SMA50) is -22.86%.
Regeneron Pharmaceuticals (NASDAQ:REGN) major shareholder Sanofi bought 190,751 shares of the stock in a transaction that occurred on Monday, May 19th. The stock was purchased at an average price of $300.04 per share, with a total value of $57,232,930.04. Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) shares advanced 3.42% in last trading session and ended the day on $307.94. REGN gross Margin is 89.50% and its return on assets is 13.90%.Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) quarterly performance is -9.39%.
XenoPortInc. (NASDAQ:XNPT) Director John Gordon Freund purchased 15,000 shares of the stock on the open market in a transaction dated Friday, May 23rd. The stock was purchased at an average cost of $3.73 per share, with a total value of $55,950.00. Following the acquisition, the director now directly owns 8,899 shares of the company’s stock, valued at approximately $33,193. XenoPort, Inc. (NASDAQ:XNPT) shares moved up 8.02% in last trading session and was closed at $4.04, while trading in range of $3.74 – $4.07. XenoPort, Inc. (NASDAQ:XNPT) year to date (YTD) performance is -29.74%.
ArQule Inc. (NASDAQ:ARQL) CEO Paolo Pucci purchased 5,000 shares of the company’s stock in a transaction dated Tuesday, May 20th. The stock was purchased at an average cost of $1.42 per share, with a total value of $7,100.00. Following the transaction, the chief executive officer now directly owns 232,280 shares of the company’s stock, valued at approximately $329,838. ArQule, Inc. (NASDAQ:ARQL) ended the last trading day at $1.40. Company weekly volatility is calculated as 6.45% and price to cash ratio as 1.22.ArQule, Inc. (NASDAQ:ARQL) showed a negative weekly performance of -3.45%.
GenVec Inc. (NASDAQ:GNVC) major shareholder Ecor1 Capital, Llc acquired 24,140 shares of GenVec stock in a transaction dated Tuesday, May 27th. The shares were purchased at an average price of $2.24 per share, with a total value of $54,073.60. GenVec Inc. (NASDAQ:GNVC) weekly performance is 7.62%. On last trading day company shares ended up $2.40. Analysts mean target price for the company is $8.50. GenVec Inc. (NASDAQ:GNVC) distance from 50-day simple moving average (SMA50) is -5.56%.